Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly's Performance Contract For Trulicity Hinges On Head-To-Head Superiority

This article was originally published in The Pink Sheet Daily

Executive Summary

Price rebates will be based on whether Trulicity is superior to other GLP-1 agonists in lowering A1C blood sugar for Harvard Pilgrim members.


Related Content

Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7
The Value Lab: Moving Value-Based Health Care From Theory To Practice
Brilinta/Bydureon’s Measurable Outcomes Are Smooth Fit For Contracts
Enbrel's First Outcomes Contract Is With Harvard Pilgrim; Others May Follow
Jardiance Outcomes-Based Contracting Push Underway, Armed With CV Claim
The Outcomes-Based Reimbursement Experiment
US Outcomes-Based Contracts: Big Uptick In Interest, But Not Execution
Merck/Aetna Pact Links Januvia Value-Based Payment To Treatment Intensification
US Retail Drug Spending Growth Slowing With No New Sovaldis In Sight


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts